Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Anti-Inflammatory drugs lift depression that Won't budge?

NCT ID NCT07804979

Disease control Sponsor: Lahore General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether adding minocycline or celecoxib to a standard antidepressant helps people with treatment-resistant depression. Treatment-resistant depression means symptoms have not improved enough with previous antidepressant treatment. About 78 adults aged 18 to 65 will receive either minocycline or celecoxib alongside fluoxetine for 12 weeks. Researchers will measure changes in depressive symptoms using the Hamilton Depression Rating Scale to see if either add-on drug improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Minocycline or celecoxib added to fluoxetine
What this could lead to
If either add-on drug works, it could offer a new option for people with depression that does not improve with standard antidepressants.
What could go wrong
This is a small, early-stage trial, so results may not apply widely. Both drugs can have side effects, and the added benefit over fluoxetine alone is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

78 people

The number who actually took part.

Started

May 2022

Finished

Sep 2023

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18-65 years. * Patients of either gender. * Patients with a current diagnosis of Major Depressive Disorder. * Voluntary outpatients who were competent to provide informed consent. * Patients with a baseline Hamilton Depression Rating Scale (HAM-D) score \>14. * Patients fulfilling the study definition of Treatment-Resistant Depression (TRD). Exclusion Criteria: * Patients with psychotic depression. * Patients already taking either of the trial drugs, based on the medical record. * Patients with substance use disorder or dependence within the previous 3 months. * Pregnant women, women planning to conceive within 3 months, or breastfeeding women. * Patients with another primary psychiatric disorder already receiving treatment. * Patients with a history of intolerance or allergy to minocycline or celecoxib. * Patients with active renal, hepatic, cardiac, or serious dermatological illness. * Patients receiving concomitant penicillin therapy or anticoagulants.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cyclopia sequence Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD) Treatment-resistant depression (TRD)

Contacts and locations

Locations

  • Lahore General Hospital, Lahore

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.